Kiadis appoints Ray Barlow, Ph.D. as Chief Business Officer and
Govert Schouten, Ph.D. as Head of Innovation to Kiadis Management
Team
- Senior executives with extensive biotechnology and
pharmaceutical industry, science, innovation and business
development experience
- Bringing
unique capabilities to unlock broad potential of Kiadis
platform
Amsterdam, The Netherlands, July 13,
2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company developing innovative NK-cell
therapeutics for patients with life-threatening diseases, today
announces that it has appointed Ray Barlow, Ph.D. as chief business
officer and Govert Schouten, Ph.D. as head of innovation. As of
today, Barlow and Schouten will report to Kiadis’ CEO, Arthur Lahr,
and will be members of the Company’s Management Team. Marcel Zwaal,
the Company’s senior vice president of corporate development, will
be leaving the Company to pursue other opportunities.
Dr. Barlow is responsible for all corporate
business development initiatives, including out-licensing, pharma
and biotech partnerships, development and commercialization
collaborations, and potential mergers and acquisitions. Dr.
Schouten is responsible for Kiadis’ intellectual property,
scientific and academic collaborations, government grants and
in-licensing of science and IP to build Kiadis’ K-NK technology
platform.
Arthur Lahr, chief executive officer of
Kiadis, commented, “Kiadis’ K-NK-cell therapy platform has
almost unlimited potential for the treatment of cancers, infectious
diseases and other life-threatening diseases. Ray and Govert have
throughout their careers led hundreds of deals with pharma, biotech
and academia, and brought in hundreds of millions in licensing fees
and government grants. They can make a huge contribution to unlock
the value of our platform, for products that we bring to market on
our own or with the help of a bigger pharmaceutical company. I want
to thank Marcel for all of his contributions to acquire and
position our K-NK technology and wish him all the best in his
future endeavors. We welcome Ray and Govert and look forward to
their contributions to build our pipeline and our K-NK-cell therapy
platform.”
With more than 20 years of experience in the
biopharmaceutical industry, Ray Barlow has served in various
leadership roles including most recently as chief executive officer
at e-therapeutics PLC where he led the turnaround of the business
and generated its first commercial deals. Previously, Dr. Barlow
worked at Amgen as executive director of corporate development and
prior to that at Crucell Vaccines where he managed business deals
in infectious diseases and vaccines. Prior to joining Crucell, Ray
founded and led his own business, BD Solutions Ltd, advising
clients on corporate development and commercialization strategies.
Dr. Barlow started his career at AstraZeneca where he held a number
of senior R&D, Business Development and Commercial roles over a
12-year period. Dr. Barlow holds a Ph.D. in macromolecular science
from the University of Manchester, UK, a BSc in Chemistry from the
University of Leeds, UK, and an MBA from Manchester Business
School, UK.
Govert Schouten brings nearly 25 years of
experience in the pharmaceutical and biotechnology industry to
Kiadis. Most recently, Dr. Schouten was the founder of Idmon
Consulting B.V., a consulting firm providing corporate development,
strategy and business development services. Prior to that, Dr.
Schouten was co-founder and chief business officer of myTomorrows
(Impatients N.V.), chief executive officer of Mucosis B.V., and
vice president, head of business development and member of the
executive committee of Crucell Vaccines. Dr. Schouten holds a
Master’s degree in behavioral sciences and a Ph.D. in tumor
virology from Leiden University, The Netherlands.
For more information, please contact:
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring LifeSciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
Dutch Translation/Nederlandse vertaling
Amsterdam, 13 juli 2020 - Kiadis Pharma
N.V. ("Kiadis") (Euronext Amsterdam en Brussel:
KDS), een biofarmaceutische onderneming
in de klinische fase gericht op ontwikkeling van innovatieve
Natural Killer Cell-therapieën voor patiënten met levensbedreigende
aandoeningen, maakt benoeming bekend van Ray Barlow, Ph.D. tot
chief business officer en Govert Schouten, Ph.D. tot hoofd
innovatie. Barlow en Schouten rapporteren aan Kiadis' CEO en treden
toe tot het Management Team. Senior Vice President Corporate
Development Marcel Zwaal heeft besloten de onderneming te
verlaten.
Dr. Barlow is verantwoordelijk voor corporate
business development waaronder uitlicentiëring, allianties met
farmaceutische en biotechnologie bedrijven, en potentiële fusies en
overnames. Dr. Schouten is verantwoordelijk voor Kiadis’
intellectuele eigendom en patent portfolio, wetenschappelijke en
academische samenwerkingsverbanden, overheidssubsidies en het
in-licentiëren van intellectueel eigendom voor de uitbouw van het
K-NK-technologieplatform.
Arthur Lahr, chief executive officer van
Kiadis, zegt over de benoemingen: "Kiadis’
K-NK-celtherapieplatform biedt nagenoeg onbeperkte mogelijkheden
voor de behandeling van kankers, infectieziekten en andere
levensbedreigende aandoeningen. Ray en Govert hebben gedurende hun
loopbaan honderden deals gedaan in de farma-, biotech- en
academische wereld en daarbij honderden miljoenen aan
licentieinkomsten en overheidssubsidies gerealiseerd. Ze kunnen een
enorme bijdrage leveren aan het ontsluiten van de waarde van ons
platformen producten zelfstandig en met hulp van grotere
farmaceutische ondernemingen richting de markt te brengen.Ik wil
Marcel hartelijk danken voor al zijn bijdragen bij de aankoop van
Cytosen in 2019 en de positionering van onze K-NK-technologie en
wens hem veel succes in zijn verdere carrière. Ik heet Ray en
Govert van harte welkom en kijk uit naar hun bijdrage aan de
uitbouw van onze pijplijn en ons K-NK-celtherapieplatform.”
Met meer dan 20 jaar ervaring in de
biofarmaceutische sector heeft Ray Barlow meerdere leidinggevende
functies vervuld, waaronder meest recentelijk als chief executive
officer bij e-therapeutics PLC waar hij de turnaround van de
onderneming leidde en de eerste commerciële deals initieerde.
Daarvoor werkte Dr. Barlow bij Amgen als directeur business
development en bij Crucell Vaccines, waar hij
verantwoordelijk was voor business development voor vaccins.
Voorafgaand aan Crucell was hij oprichter/eigenaar van BD Solutions
Ltd, dat klanten adviseerde op het gebied van bedrijfsontwikkeling
en commercialiseringsstrategieën. Dr. Barlow startte zijn carrière
bij AstraZeneca, waar hij gedurende 12 jaar een aantal senior
R&D-, business development- en commerciële functies bekleedde.
Dr. Barlow heeft een Ph.D. in macromoleculaire wetenschap aan de
Universiteit van Manchester, VK, een BSc in Chemie aan de
Universiteit van Leeds, VK, en een MBA van Manchester Business
School, VK.
Govert Schouten heeft 25 jaar ervaring in de
farmaceutische en biotechnologische sector. Recentelijk was Dr.
Schouten oprichter van Idmon Consulting B.V., een adviesbureau op
het gebied van corporate development, strategie en business
development. Daarvoor was Dr. Schouten medeoprichter en chief
business officer van myTomorrows (Impatients N.V.), chief executive
officer van Mucosis B.V., en vice-president business development en
lid van het management team van Crucell Vaccines. Dr. Schouten
heeft een Master in gedragswetenschappen en een Ph.D. in
tumorvirologie van de Universiteit Leiden.
Dit persbericht vormt een vertaling van het
gepubliceerde Engelstalige persbericht. Bij eventuele verschillen
is de tekst van het Engelstalige persbericht altijd
bepalend.
About Kiadis’ K-NK-cell
Therapies Kiadis’ NK-cell programs consist of
off-the-shelf and haplo donor cell therapy products for the
treatment of liquid and solid tumors as adjunctive and stand-alone
therapies.
The Company’s NK-cell PM21 particle technology
enables improved ex vivo expansion and activation of anti-cancer
cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis’
proprietary off-the-shelf NK-cell platform is based on NK-cells
from unique universal donors. The Kiadis off-the-shelf K-NK
platform can make NK-cell therapy product rapidly and economically
available for a broad patient population across a potentially wide
range of indications.
Kiadis is clinically developing K-NK003 for the
treatment of relapse/refractory acute myeloid leukemia. The Company
is also developing K-NK002, which is administered as an adjunctive
immunotherapeutic on top of HSCT and provides functional, mature
and potent NK-cells from a haploidentical family member. In
addition, the Company has pre-clinical programs evaluating NK-cell
therapy for the treatment of solid tumors.
About Relapsed/Refractory Acute Myeloid
Leukemia (R/R AML) Acute myeloid leukemia (AML) is the
most common type of acute leukemia in adults and has the lowest
survival rate of all leukemias. AML relapse affects nearly half of
all leukemia patients who achieve remission after initial treatment
and can continue to occur several months to several years after
treatment with the majority of relapses occurring within two to
three years of the initial treatment. Patients with relapsed or
refractory leukemia have limited treatment options and poor
survival rates.
The goal of treatment for AML is to put the
leukemia into complete remission and to keep it that way. Unlike
conventional chemotherapy options, which primarily target dividing
cells, immunotherapeutic therapies aim at directing an immune
response against tumor cells. Natural Killer (NK) cells are
effector lymphocytes of the innate immune system capable of
exerting anti-AML activity. The K-NK cell platform is a cell-based
immunotherapy to treat patients with advanced blood cancer.
About KiadisFounded in 1997,
Kiadis is building a fully integrated biopharmaceutical company
committed to developing innovative therapies for patients with
life-threatening diseases. With headquarters in Amsterdam, The
Netherlands, and offices and activities across the United States,
Kiadis is reimagining medicine by leveraging the natural strengths
of humanity and our collective immune system to source the best
cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’
officers’ current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person’s officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.